Conference Coverage

How to avoid severe diarrhea from apremilast


 

EXPERT ANALYSIS FROM SDEF HAWAII DERMATOLOGY SEMINAR

The intensified subcutaneous regimen consisted of 17.5 mg/week initially, escalated to 22.5 mg/week after 8 weeks if a patient hadn’t achieved at least a PASI 50 response at that point. The primary outcome, the PASI 75 response at week 16, was 41% in the subcutaneous methotrexate group and 10% in controls, with a maximum PASI 75 rate of 51% seen beginning at week 24. The week 4 and 8 PASI 50 rates were 50% and 58%, respectively, with methotrexate versus 3% and 17% in placebo-treated controls. The subcutaneous regimen was generally well tolerated, with no serious infections or malignancies arising during 52 weeks (Lancet. 2017 Feb 4;389[10068]:528-37).

Dr. Wu reported receiving research funding from AbbVie, Amgen, Eli Lilly, Janssen, Novartis, and Regeneron.

The Global Academy for Medical Education/SDEF and this news organization are owned by the same parent company.

Pages

Recommended Reading

Arthritis limits physical activity the most in the South
MDedge Rheumatology
FDA approves IL-23 antagonist for plaque psoriasis
MDedge Rheumatology
FDA approves certolizumab label update for pregnancy, breastfeeding
MDedge Rheumatology
Study using U.K. data quantifies infection risk associated with psoriasis
MDedge Rheumatology
TB in 2017: Good news and bad news
MDedge Rheumatology
Most PsA patients discontinue initial biologic within 12 months
MDedge Rheumatology
MDedge Daily News: Does more marijuana mean fewer opioids?
MDedge Rheumatology
Reassurance for women taking certolizumab during pregnancy
MDedge Rheumatology
AbbVie, Samsung Bioepis settle suits with delayed U.S. entry for adalimumab biosimilar
MDedge Rheumatology
New PsA questionnaire fails to beat existing early screening methods
MDedge Rheumatology